Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Investments (2016)

Historic Long-Term Investments for Northwest Biotherapeutics (NWBO) over the last 7 years, with Q2 2016 value amounting to $77000.0.

  • Northwest Biotherapeutics' Long-Term Investments fell 8958.05% to $77000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was $77000.0, marking a year-over-year decrease of 8958.05%. This contributed to the annual value of $349000.0 for FY2015, which is 8017.05% down from last year.
  • Northwest Biotherapeutics' Long-Term Investments amounted to $77000.0 in Q2 2016, which was down 8958.05% from $214000.0 recorded in Q1 2016.
  • Northwest Biotherapeutics' 5-year Long-Term Investments high stood at $1.8 million for Q4 2014, and its period low was $17000.0 during Q4 2012.
  • Moreover, its 5-year median value for Long-Term Investments was $77000.0 (2016), whereas its average is $394923.1.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 229636.36% in 2015, then tumbled by 8958.05% in 2016.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Long-Term Investments stood at $17000.0 in 2012, then changed by 0.0% to $17000.0 in 2013, then soared by 10252.94% to $1.8 million in 2014, then plummeted by 80.17% to $349000.0 in 2015, then plummeted by 77.94% to $77000.0 in 2016.
  • Its Long-Term Investments was $77000.0 in Q2 2016, compared to $214000.0 in Q1 2016 and $349000.0 in Q4 2015.